Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost uptake of a shot that’s posted flattening sales after an initially strong ...

Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. | Eli Lilly is making investments ...

The stock now trades at a dividend yield of 6.5%. Despite continued pricing pressure, Pfizer stock looks cheap for investors today. Investors may have thought they were out of the woods as Pfizer ...

A recent study found that older adults who take a daily multivitamin may slow their biological aging by up to 4 months. The researchers note that multivitamins don't add years to life span, but they ...

Glen Santangelo Barclays Bank PLC, Research Division. All right. Good morning, everyone. Thank you for joining us for our next presentation. We're excited to be hosting Amneal Pha ...

The co-founders of the Covid-19 vaccine developer BioNTech plan to leave the biotech to start a new mRNA-focused company ...

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

Roche's shares declined sharply after its breast cancer drug, giredestrant, failed a key trial. The drug didn't show meaningful progress when combined with Ibrance. Despite this, analysts see ...

Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate(1) . The Drug ...